Pulmonary Arterial Hypertension Market Size & Share 2025 - 2034

Pulmonary Arterial Hypertension Market Size

The global pulmonary arterial hypertension (PAH) market size was valued at USD 8.3 billion in 2024. The market is expected to grow from USD 8.7 billion in 2025 to USD 13.9 billion in 2034, at a CAGR of 5.4% during the forecast period, according to the latest report published by Global Market Insights Inc.

This growth is attributed to the increasing incidence of pulmonary arterial hypertension globally, government agencies and regulatory bodies like the FDA and EMA are actively supporting PAH drug development, and advancement in drug therapies. In addition, the advancement in diagnostic technologies and biomarker screening methods has improved the early detection of pulmonary arterial hypertension (PAH). According to the National Institutes of Health (NIH) data from 2023, the average time from symptom onset to diagnosis decreased from 2.5 years to 1.8 years between 2021 and 2023. The Centers for Disease Control and Prevention (CDC) reported in 2022 that diagnosis rates increased by 28% compared to 2021, primarily due to enhanced screening protocols.
 

The growing awareness among medical professionals and patients has enabled earlier treatment initiation, with the American Heart Association noting a 35% reduction in hospital admissions for PAH patients diagnosed within six months of symptom onset in 2023, that further contributes to market growth.
 

Pulmonary arterial hypertension (PAH) is a form of pulmonary hypertension in which the pulmonary arteries responsible for carrying blood from the heart to the lungs become narrowed, thickened, or blocked. Major players in the industry are United Therapeutics, Janssen Pharmaceuticals (Johnson & Johnson), Gilead Sciences, Bayer and Pfizer. These players dominated the market by adopting various strategies such as product expansion and establishing global distribution networks.
 

Pulmonary arterial hypertension market has witnessed steady growth, growing from USD 7.3 billion in 2021 to USD 7.9 billion in 2023. The growth of the market is driven by the adoption of innovative therapies targeting multiple disease pathways. Drugs like endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin analogs are increasingly used in combination to enhance efficacy. These therapies offer better symptom control and slow disease progression. The launch of new oral fixed-dose combinations, such as macitentan with tadalafil, simplifies treatment regimens and improves patient adherence, making them highly attractive in clinical practice.
 

Precision medicine in pulmonary arterial hypertension (PAH) management involves customizing treatments according to genetic markers, biomarkers, and patient-specific characteristics. For instance, according to the National Institutes of Health (NIH), in 2023, USD 419 million was allocated for precision medicine research in PAH and related cardiovascular diseases. Moreover, the U.S. FDA approved 8 precision medicine-based therapies for PAH between 2021 and 2023. This personalized approach improves treatment effectiveness while minimizing side effects.
 

Additionally, the use of genetic testing and biomarker analysis, including B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), enables patient stratification and targeted treatment selection. As per the European Medicines Agency's 2022 report, biomarker-guided therapy showed a 35% improvement in patient outcomes compared to standard treatments. The implementation of personalized treatment strategies contributes to improved patient outcomes and quality of life, positioning precision medicine as a significant factor in PAH market growth.
 

The pulmonary arterial hypertension (NRT) market is gaining momentum through increased investment in healthcare infrastructure across developing regions, particularly in Asia-Pacific and Latin America. Emerging economies like China, India, and Brazil are witnessing increased access to PAH treatments due to improved healthcare infrastructure and government-led awareness campaigns.
 

Pulmonary Arterial Hypertension Market Trends

• The global market experiencing dynamic transformation driven by the increasing prevalence of pulmonary arterial hypertension (PAH), with an estimated 15-50 cases per million population globally in 2023, according to the World Health Organization. The U.S. Centers for Disease Control and Prevention reported approximately 20,000 PAH-related hospitalizations in 2022, particularly among aging populations and individuals who have survived congenital heart disease.
   
• Moreover, the improvement in healthcare systems' diagnostic capabilities enables earlier detection of cases, which increases the demand for long-term treatments. For instance, according to the National Health Commission of China, PAH diagnoses in Asia-Pacific increased by 12% between 2021 and 2023, driven by artificial intelligence-enabled diagnostics and improved healthcare access. North America maintains the largest market share, with the U.S. National Institutes of Health reporting a 15% increase in PAH research funding from 2021 to 2024.
   
• The FDA approved 55 novel drugs in 2023 and 37 in 2022, with approximately 25% receiving fast-track designation. The EMA approved 89 medicines in 2023, with 41% qualifying for accelerated assessment. These accelerated pathways have facilitated rapid market entry for medications such as sotatercept. Drugs like sotatercept have benefited from these pathways, enabling quicker market entry. Orphan drug status ensures premium pricing and extended exclusivity, encouraging innovation in rare disease treatment.
   
• Moreover, manufacturers are investing in regional production facilities, especially in Asia-Pacific, to reduce costs and improve access. Biosimilars are entering the market, offering affordable alternatives to branded therapies. This trend supports broader treatment availability and helps overcome pricing barriers in emerging markets.
   
• Further, pharmaceutical companies are increasingly engaging in strategic partnerships and mergers to expand their PAH portfolios. Larger firms acquire smaller biotech companies with promising early-stage therapies to mitigate research and development risks and accelerate innovation.
   
• These deals often focus on late-stage assets to ensure quicker returns and regulatory approval. This consolidation trend enhances pipeline strength, fosters innovation, and improves market competitiveness, especially in the biologics and gene therapy segments.
   
• Additionally, combination therapies are becoming the standard of care in PAH management due to their superior efficacy over monotherapy. Regimens combining endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin analogs are widely adopted. Fixed-dose combinations like macitentan + tadalafil simplify dosing and improve compliance.
   
• This trend is driving innovation in drug formulation and expanding treatment options for various patient subgroups.
   
• Lastly, campaigns by organizations like the American Lung Association and World Heart Federation are raising awareness about PAH symptoms, promoting early diagnosis, and educating caregivers. These efforts reduce diagnostic delays and stigma, increase treatment uptake, and influence policy changes.
   
• Advocacy groups also play a vital role in shaping clinical trials designs and market access strategies, making them powerful market influencers, that further contributes to market growth.
   

Pulmonary Arterial Hypertension Market Analysis

In 2021, the global market was valued at USD 7.3 billion. The following year, it saw a slight increase to USD 7.6 billion, and by 2023, the market further climbed to USD 7.9 billion.
 

Based on drug class, the global market is divided into prostacyclin and prostacyclin analogs, soluble guanylate cyclase (SGC) stimulatory, endothelin receptor antagonist (ERA), phosphodiesterase 5 (PDE-5), vasodilators and other drug classes. The endothelin receptor antagonist (ERA) segment accounted for 37.3% of the market in 2024. The segment is expected to exceed USD 5.2 billion by 2034, growing at a CAGR of 5.4% during the forecast period.
 

• Endothelin receptor antagonists (ERAs) effectively block the action of endothelin-1, a potent vasoconstrictor implicated in PAH pathogenesis. Their ability to reduce pulmonary vascular resistance and improve exercise capacity makes them a preferred choice for long-term management. Drugs like bosentan, ambrisentan, and macitentan have shown significant improvements in clinical outcomes, including delayed disease progression and reduced hospitalization rates.
   
• ERAs are primarily available in oral formulations, which enhance patient convenience and adherence compared to intravenous or inhaled therapies. This aligns with the broader market trend favouring oral drugs for chronic conditions. The ease of administration supports outpatient care models and reduces the burden on healthcare infrastructure, making ERAs more accessible and scalable.
   
• Further, prostacyclin and prostacyclin analogs segment is expected to grow with the fastest CAGR of 5.9% during the analysis period. Prostacyclin therapies are highly effective in treating advanced PAH by dilating pulmonary arteries and inhibiting platelet aggregation.
   
• The shift from intravenous to oral and inhaled prostacyclin analogs has significantly improved patient convenience and adherence. Products like inhaled treprostinil and oral selexipag offer targeted delivery with fewer side effects and reduced hospitalization.
   

Based on the route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous and inhalation. The oral segment dominated the market in 2024 with a revenue of USD 6.1 billion.
 

• Oral therapies are preferred by patients due to ease of administration, especially for chronic conditions like PAH. Unlike intravenous or inhaled options, oral drugs eliminate the need for hospital visits or complex devices, improving treatment adherence and quality of life.
   
• Oral formulations generally exhibit better safety profiles and fewer systemic side effects compared to injectable therapies. This makes them suitable for long-term use and for patients with comorbidities. Drugs like sildenafil and tadalafil are well-tolerated and widely prescribed, contributing to the sustained growth of the oral segment.
   
• In addition, oral prostacyclin analogs like selexipag and oral treprostinil are gaining traction due to their ability to delay disease progression without the risks of IV therapy. These agents offer similar efficacy with superior convenience, reinforcing the shift toward oral dominance. Their commercialization is expanding the oral segment beyond traditional drug classes.
   
• The intravenous segment of the pulmonary arterial hypertension (PAH) market is projected to grow rapidly due to its ability to induce swift vasodilation and significantly improve hemodynamic parameters. These therapies are considered the gold standard for high-risk patients, as they effectively reduce mortality and hospitalization rates.
   
• Despite the complexity of administration, their clinical effectiveness ensures sustained preference among healthcare providers. Future advancements in formulation and delivery methods may further enhance usability, driving continued adoption and market expansion.
   
• Intravenous (IV) therapies for pulmonary arterial hypertension (PAH) are covered under specialized reimbursement programs in several regions. According to the Centers for Medicare & Medicaid Services (CMS), in 2023, approximately 85% of PAH-related IV therapies were covered under Medicare Part B, with an average reimbursement rate of USD 1,200-1,500 per treatment cycle.
   

Based on type, the pulmonary arterial hypertension market is classified into branded and generics. The branded segment dominated the market in 2024 with USD 4.8 billion and is growing with a CAGR of 5.2% during the forecast period.
 

• Branded drugs dominate the PAH market due to extensive clinical trials demonstrating their safety, efficacy, and long-term benefits. Physicians prefer prescribing branded medications like Tracleer, Opsumit, and Adcirca because of their proven track records across diverse patient populations.
   
• Major pharmaceutical companies are driving innovation in the branded PAH segment by introducing advanced formulations, combination therapies, and novel mechanisms of action. Notable launches such as OPSYNVI (macitentan + tadalafil) and WINREVAIR (sotatercept) have broadened treatment options and reinforced the segment’s leadership.
   
• These breakthroughs offer differentiated clinical value, attract early adopters, and stimulate market growth. As research and development efforts intensify, the branded segment is expected to remain a key driver of therapeutic advancement and competitive differentiation in the PAH market.
   
• The generics segment growing with a CAGR of 5.6% during the analysis period. The market growth for generics segment is driven by easy affordability that makes them highly attractive to both patients and healthcare systems, especially in regions with limited insurance coverage or budget constraints.
   
• As PAH is a chronic condition requiring long-term treatment, generics offer a sustainable solution for cost-sensitive populations, driving their adoption and market growth.
   

Based on age group, the pulmonary arterial hypertension market is divided into pediatric, adults, and geriatrics. The adults age group segment was anticipated to be worth of USD 5.4 billion in 2024 and is expected to grow at 5.7% CAGR during the forecast period.
 

• PAH is most commonly diagnosed in adults aged 30-60, with incidence increasing with age. This demographic is more likely to present with comorbidities such as connective tissue disorders and systemic hypertension, which contribute to PAH development. As diagnostic capabilities improve, more adult cases are identified, expanding the treatment pool and driving demand for targeted therapies.
   
• For instance, according to the National Institutes of Health (NIH) data from 2023, Pulmonary Arterial Hypertension (PAH) affects approximately 15-25 people per million population in the U.S., primarily in adults aged 30-60 years.
   
• Moreover, adults form the majority of participants in PAH clinical trials, leading to more robust data on drug efficacy and safety for this age group. This enhances physician confidence in prescribing approved therapies and accelerates regulatory approvals. The adult-centric trial design also ensures that most new drugs are optimized for this population.
   
• Moreover, the geriatric segment in expected to reach USD 3.4 billion by the end of 2034. The growth of this segment is driven due to global rise in the elderly population that has led to a significant increase in PAH diagnosis among individuals aged 65 and above.
   
• Pharmaceutical companies are developing therapies with better tolerability and simplified dosing for elderly patients. Oral and inhaled formulations are preferred over intravenous options due to ease of use and reduced risk of complications. This customization enhances adherence and outcomes, making the geriatric segment a focal point for innovation and growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, pulmonary arterial hypertension market is classified into hospitals, specialty clinics, and other end users. The hospitals segment dominated the market in 2024 and is expected to reach USD 7.3 billion by 2034.
 

• Hospitals manage advanced pulmonary arterial hypertension (PAH) cases that require continuous monitoring and intravenous treatments. These facilities provide access to specialized medical teams, including cardiologists and pulmonologists, who administer complex therapies such as continuous intravenous prostacyclin infusions.
   
• According to the Centers for Medicare & Medicaid Services (CMS), PAH-related hospitalizations rose by 15% between 2021 and 2023. This increase highlights the growing burden of the disease and the need for specialized care.
   
• Hospitals and advanced care facilities play a critical role by offering access to expert medical teams including cardiologists and pulmonologists who are equipped to administer complex therapies such as continuous intravenous prostacyclin infusions. These settings ensure timely intervention and optimized treatment outcomes for high-risk patients.
   
• Hospital-administered PAH therapies often qualify for reimbursement under inpatient or specialty care programs. This financial support encourages physicians to prescribe high-cost branded drugs and combination therapies, which are more likely to be administered in hospital settings. Reimbursement policies thus play a pivotal role in driving hospital-based treatment uptake, that further contributes to market growth.
   
• Moreover, the specialty clinics segment is growing with a significant CAGR of 5.7% during the analysis period. Specialty clinics often provide more cost-effective care for chronic conditions as compared to hospitals.
   

North America pulmonary arterial hypertension Market
 

The North America market dominated the global market with a market share of 52.4% in 2024.
 

• North America, particularly the United States, shows a high prevalence of pulmonary arterial hypertension (PAH). For instance, the Centers for Disease Control and Prevention (CDC) reports that lifestyle factors such as obesity (affecting 41.9% of adults in 2021), smoking (12.5% of adults in 2021), and cardiovascular conditions contribute to PAH incidence.
   
• The region's established healthcare infrastructure supports routine screening programs and promotes disease awareness, enabling early diagnosis and treatment. According to the American Heart Association's 2023 statistics, these factors have led to a 25% increase in diagnosed PAH cases since 2021, contributing to an expanding patient population and sustained demand for PAH treatments.
   

The U.S. pulmonary arterial hypertension market was valued at USD 3.6 billion and USD 3.7 billion in 2021 and 2022, respectively. The market size reached USD 4 billion in 2024, growing from USD 3.9 billion in 2023.
 

• The U.S. has a rising prevalence of PAH, especially among aging populations and individuals with comorbidities like COPD and connective tissue disorders. Improved awareness and access to advanced diagnostic tools such as echocardiography and biomarker testing enable earlier detection. This leads to timely treatment initiation and expands the patient pool, significantly boosting market demand.
   
• U.S.-based pharmaceutical companies like United Therapeutics and Johnson & Johnson are heavily investing in PAH research. Numerous Phase I and II trials are underway for novel therapies, including prostacyclin analogs and endothelin receptor antagonists.
   
• Government agencies like the NIH provide grants and funding for PAH research and innovation. Collaborative efforts between public institutions, pharma companies, and non-profits enhance drug development and awareness. These initiatives strengthen the ecosystem for PAH care and contribute to sustained market expansion.
   

Europe pulmonary arterial hypertension Market
 

Europe market accounted for USD 1.7 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The European region is witnessing a rising incidence of pulmonary arterial hypertension (PAH), particularly among elderly individuals and patients with connective tissue disorders. According to Eurostat, the proportion of Europe’s population aged 65 and above is projected to reach 24% by 2025.
   
• This demographic shift is expected to contribute to a higher prevalence of chronic cardiovascular conditions, including PAH, thereby driving demand for specialized care and advanced treatment options across the region.
   
• European regulatory bodies such as the EMA support PAH drug development through orphan drug designations and accelerated approvals. Additionally, national healthcare systems offer robust reimbursement policies, making high-cost therapies more accessible. These frameworks encourage pharmaceutical investment and ensure broader patient access to innovative treatments.
   

Germany dominates the European pulmonary arterial hypertension market, showcasing strong growth potential.
 

• Germany’s aging population is contributing to a higher incidence of PAH, particularly among individuals with comorbidities like connective tissue disorders and cardiovascular conditions. As life expectancy increases, so does the need for long-term management of chronic diseases. This demographic trend expands the patient pool and drives sustained demand for PAH therapies.
   
• Germany’s statutory health insurance system covers most PAH treatments, including high-cost branded drugs and hospital-based therapies. This financial support reduces barriers to access and encourages physicians to prescribe advanced therapies.
   

Asia Pacific pulmonary arterial hypertension Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 5.7% during the analysis timeframe.
 

• Asia Pacific is witnessing a surge in PAH cases due to increasing incidence of risk factors such as congenital heart disease, connective tissue disorders, and chronic respiratory conditions. Urbanization, aging populations, and lifestyle changes like smoking and sedentary behavior further contribute to disease burden.
   
• Asia Pacific is becoming a hub for PAH-related clinical trials, with growing interest in novel drug classes and delivery systems. Pharmaceutical companies are exploring combination therapies, inhaled formulations, and disease-modifying agents like sotatercept. This research activity is accelerating innovation and expanding treatment options across the region.
   

China pulmonary arterial hypertension market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China is rapidly upgrading its healthcare infrastructure, including the establishment of specialized cardiopulmonary centers and access to advanced diagnostics. This enables earlier detection and better disease management.
   
• China’s domestic pharmaceutical industry is producing generic and biosimilar PAH drugs at lower costs. This improves affordability and access, especially in rural and semi-urban areas. Local production also supports faster distribution and regulatory approvals, contributing to market expansion.
   
• China’s National Medical Products Administration (NMPA) is accelerating approvals for innovative PAH therapies. Recent approvals include sustained-release oral formulations and novel drug classes like soluble guanylate cyclase stimulators. This regulatory support encourages pharmaceutical investment and speeds up market entry.
   

Latin American pulmonary arterial hypertension Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil is experiencing an increase in respiratory and cardiovascular diseases due to aging populations, urban pollution, and lifestyle factors such as poor diet and lack of exercise. These conditions are major contributors to PAH, expanding the patient base and driving demand for long-term therapeutic solutions across the country.
   
• Brazil’s pharmaceutical sector is producing generic PAH drugs locally, making treatment more affordable and accessible. This is especially important in rural areas and among uninsured populations. The availability of cost-effective alternatives is expanding the market and reducing dependency on imported branded drugs.
   

Middle East and Africa pulmonary arterial hypertension Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia has experienced a notable rise in public and clinical awareness of pulmonary arterial hypertension (PAH), leading to earlier diagnosis and improved treatment outcomes.
   
• Government-led health campaigns enhanced medical education, and increased access to diagnostic tools such as echocardiography and biomarker testing have significantly reduced underdiagnosis across the country.
   
• Events like the Saudi Association for Pulmonary Hypertension (SAPH) Conference play a pivotal role in advancing the field.
   
• These gatherings bring together global experts to share the latest research, clinical practices, and therapeutic innovations. They foster collaboration between institutions, promote the adoption of new therapies, and help shape national treatment standards.
   

Pulmonary Arterial Hypertension Market Share

The pulmonary arterial hypertension (PAH) market features a dynamic and moderately consolidated competitive landscape, shaped by a mix of established pharmaceutical giants and emerging biotech innovators. The top 5 market players in the market, including Johnson & Johnson, Gilead Sciences, Pfizer, United Therapeutics, and Bayer maintain a dominant position account for ~75% of the market share through strategic investments in research and development, global expansion, regulatory alignment, and the development of patient-centric therapies that address the complex needs of PAH management.
 

To strengthen their market presence, these companies are employing multi-faceted strategies including mergers and acquisitions, strategic alliances, and value-based pricing models. These approaches aim to improve access to advanced PAH treatments, enhance affordability, and address unmet clinical needs particularly in regions with rising PAH prevalence and limited therapeutic options.
 

Emerging companies are advancing market development through technological innovations in drug delivery systems, oral and inhaled formulations, and digital health integration. Their influence is significant in Asia-Pacific, Latin America, and the Middle East regions, where improving healthcare infrastructure and growing PAH awareness drive the adoption of new treatments.
 

The PAH market continues to expand with increased competition and diversified treatment options. Companies are adapting their product portfolios to meet the global demand for effective and accessible therapies, supporting continued market growth and innovation.
 

Pulmonary Arterial Hypertension Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the pulmonary arterial hypertension industry are as mentioned below:

• Bayer
• F. Hoffmann La Roche
• GlaxoSmithKline (GSK)
• Gilead Sciences
• Gmax Biopharm
• Gossamer Bio
• Galectin Therapeutics 
• Janssen Pharmaceuticals (Johnson & Johnson)
• Liquidia Technologies
• Merck KGaA
• Novartis
• Pfizer
• Resverlogix
• United Therapeutics

• United Therapeutics

United Therapeutics leads the market with a share of ~21.5% in 2024. Pioneer in prostacyclin therapies with strong portfolio including Remodulin and Tyvaso. Drives innovation in inhaled and subcutaneous delivery systems, significantly improving patient outcomes and expanding access to advanced PAH treatments.
 

• Pfizer

Pfizer leverages global reach and robust research and development to support PAH therapies like Revatio (sildenafil). Focuses on affordability and accessibility, contributing to widespread adoption of oral treatments and enhancing long-term disease management.
 

• GlaxoSmithKline

GlaxoSmithKline known for strategic partnerships and a diversified PAH pipeline. GSK emphasizes patient-centric innovation and regulatory excellence, helping shape treatment standards and expand therapeutic options in emerging and developed markets.
 

Pulmonary Arterial Hypertension Industry News

• In May 2025, Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA (treprostinil) inhalation powder, a prostacyclin analog for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability.
   
• In March 2024, Merck announced that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk for the treatment of adults with pulmonary arterial hypertension FDA. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.
   
• In March 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor for the chronic treatment of adults with pulmonary arterial hypertension.
   

The pulmonary arterial hypertension market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Prostacyclin and prostacyclin analogs
• Soluble guanylate cyclase (SGC) stimulators
• Endothelin receptor antagonist (ERA)
• Phosphodiesterase 5 (PDE-5)
• Vasodilators
• Other drug classes    

Market, By Route of Administration

• Oral
• Intravenous
• Inhalation

Market, By Type

• Branded
• Generics

Market, By Age Group

• Pediatric
• Adult
• Geriatric

Market, By End Use

• Hospitals
• Specialty clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE